153 related articles for article (PubMed ID: 33847416)
1. L1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumours, well-differentiated papillary mesothelial tumours and malignant mesotheliomas.
Karpathiou G; Casteillo F; Dridi M; Papoudou-Bai A; Dumollard JM; Peoc'h M
Histopathology; 2021 Aug; 79(2):272-274. PubMed ID: 33847416
[No Abstract] [Full Text] [Related]
2. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
Hung YP; Chirieac LR
Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
[TBL] [Abstract][Full Text] [Related]
3. TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma.
Itami H; Fujii T; Nakai T; Takeda M; Kishi Y; Taniguchi F; Terada C; Okada F; Nitta Y; Matsuoka M; Sasaki S; Sugimoto S; Uchiyama T; Morita K; Kasai T; Kawaguchi R; Ohbayashi C
Hum Pathol; 2021 May; 111():59-66. PubMed ID: 33667423
[TBL] [Abstract][Full Text] [Related]
4. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.
Stevers M; Rabban JT; Garg K; Van Ziffle J; Onodera C; Grenert JP; Yeh I; Bastian BC; Zaloudek C; Solomon DA
Mod Pathol; 2019 Jan; 32(1):88-99. PubMed ID: 30171198
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations.
Taheri ZM; Mehrafza M; Mohammadi F; Khoddami M; Bahadori M; Masjedi MR
Arch Pathol Lab Med; 2008 Apr; 132(4):694-7. PubMed ID: 18384222
[TBL] [Abstract][Full Text] [Related]
6. Peritoneal adenomatoid (microcystic) mesothelioma.
Mori D; Kido S; Hiraki M; Sumi K; Ureshino N; Masuda M; Nabeshima K; Akashi M
Pathol Int; 2020 Nov; 70(11):876-880. PubMed ID: 32881200
[TBL] [Abstract][Full Text] [Related]
7. Adenomatoid Tumor: A Review of Pathology With Focus on Unusual Presentations and Sites, Histogenesis, Differential Diagnosis, and Molecular and Clinical Aspects With a Historic Overview of Its Description.
Karpathiou G; Hiroshima K; Peoc'h M
Adv Anat Pathol; 2020 Nov; 27(6):394-407. PubMed ID: 32769378
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
9. Mesotheliomas and Benign Mesothelial Tumors: Update on Pathologic and Imaging Findings.
Bonde A; Singh R; Prasad SR; Kamireddy D; Aggarwal A; Ramani N; Saboo S; Shanbhogue K; Dasyam AK; Katabathina VS
Radiographics; 2023 Mar; 43(3):e220128. PubMed ID: 36757881
[TBL] [Abstract][Full Text] [Related]
10. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors.
Goldblum J; Hart WR
Am J Surg Pathol; 1995 Oct; 19(10):1124-37. PubMed ID: 7573671
[TBL] [Abstract][Full Text] [Related]
11. Mesothelial lesions of the paratesticular region.
Perez-Ordonez B; Srigley JR
Semin Diagn Pathol; 2000 Nov; 17(4):294-306. PubMed ID: 11202546
[TBL] [Abstract][Full Text] [Related]
12. BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.
Erber R; Warth A; Muley T; Hartmann A; Herpel E; Agaimy A
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):67-73. PubMed ID: 30640754
[TBL] [Abstract][Full Text] [Related]
13. New developments in mesothelial pathology.
Churg A
Histopathology; 2024 Jan; 84(1):136-152. PubMed ID: 37694811
[TBL] [Abstract][Full Text] [Related]
14. Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases.
Weissferdt A; Kalhor N; Suster S
Ann Diagn Pathol; 2011 Feb; 15(1):25-9. PubMed ID: 21106421
[TBL] [Abstract][Full Text] [Related]
15. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical evidence for mesothelial origin of paratesticular adenomatoid tumour.
Delahunt B; Eble JN; Nacey JN; Thornton A
Histopathology; 2001 May; 38(5):479. PubMed ID: 11422488
[No Abstract] [Full Text] [Related]
17. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
Cakir E; Demirag F; Aydin M; Unsal E
Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
[TBL] [Abstract][Full Text] [Related]
18. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.
Lee M; Alexander HR; Burke A
Pathology; 2013 Aug; 45(5):464-73. PubMed ID: 23846294
[TBL] [Abstract][Full Text] [Related]
19. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation.
Goode B; Joseph NM; Stevers M; Van Ziffle J; Onodera C; Talevich E; Grenert JP; Yeh I; Bastian BC; Phillips JJ; Garg K; Rabban JT; Zaloudek C; Solomon DA
Mod Pathol; 2018 Apr; 31(4):660-673. PubMed ID: 29148537
[TBL] [Abstract][Full Text] [Related]
20. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]